This is the preview version of the Wisconsin State Legislature site.
Please see http://docs.legis.wisconsin.gov for the production version.
SB70-AA3,80,54 1. One member representing the University of Wisconsin School of Medicine
5and Public Health.
SB70-AA3,80,66 2. One member representing the Medical College of Wisconsin.
SB70-AA3,80,77 3. One member who has a spinal cord injury.
SB70-AA3,80,88 4. One member who is a family member of a person with a spinal cord injury.
SB70-AA3,80,99 5. One member who is a veteran who has a spinal cord injury.
SB70-AA3,80,1110 6. One member who is a physician specializing in the treatment of spinal cord
11injuries.
SB70-AA3,80,1212 7. One member who is a researcher in the field of neurosurgery.
SB70-AA3,80,1413 8. One member who is a researcher employed by the veterans health
14administration of the U.S. department of veterans affairs.
SB70-AA3,80,1715 (b) If the department of health services is unable to appoint a member specified
16in par. (a) 1. to 8., the department of health services may appoint a member
17representing the general public in lieu of the member so specified.
SB70-AA3,77 18Section 77. 255.45 of the statutes is created to read:
SB70-AA3,80,20 19255.45 Spinal cord injury research grants and symposia. (1)
20Definitions.
In this section:
SB70-AA3,80,2121 (a) “Council” means the spinal cord injury council.
SB70-AA3,80,2222 (b) “Grant program” means the program established under sub. (2).
SB70-AA3,81,5 23(2) Grant program. The department shall establish a program to award
24grants, from the appropriation under s. 20.435 (1) (b), to persons in this state for
25research into spinal cord injuries. The purpose of the grants is to support research

1into new and innovative treatments and rehabilitative efforts for the functional
2improvement of people with spinal cord injuries, and research topics may include
3pharmaceutical, medical device, brain stimulus, and rehabilitative approaches and
4techniques. Grant recipients shall agree to present their research findings at
5symposia held by the department under sub. (3).
SB70-AA3,81,8 6(3) Symposia. The department may hold symposia every 2 years for recipients
7of grants under the grant program to present findings of research supported by the
8grants.
SB70-AA3,81,12 9(4) Grant reports. By January 15 of each year, the department shall submit
10an annual report to the appropriate standing committees of the legislature under s.
1113.172 (3) that identifies the recipients of grants under the grant program and the
12purposes for which the grants were used.
SB70-AA3,81,13 13(5) Council. (a) The council shall do all of the following:
SB70-AA3,81,1514 1. Develop criteria for the department to evaluate and award grants under the
15grant program.
SB70-AA3,81,1716 2. Review and make recommendations to the department on applications
17submitted under the grant program.
SB70-AA3,81,1818 3. Perform other duties specified by the department.
SB70-AA3,81,2219 (b) Each member of the council shall disclose in a written statement any
20financial interest in any organization that the council recommends to receive a grant
21under the grant program. The council shall include the written statements with its
22recommendations to the department on grant applications.
SB70-AA3,9119 23Section 9119. Nonstatutory provisions; Health Services
SB70-AA3,82,3
1(1) Spinal cord injury council; initial appointments. Notwithstanding the
2length of terms specified for the members of the spinal cord injury council under s.
315.197 (20) (a) (intro.), initial appointments to the council shall be made as follows:
SB70-AA3,82,64 (a) The members appointed under s. 15.197 (20) (a) 1., 3., 5., and 7., or in lieu
5of those members under s. 15.197 (20) (b), shall be appointed for terms expiring on
6July 1, 2025.
SB70-AA3,82,97 (b) The members appointed under s. 15.197 (20) (a) 2., 4., 6., and 8., or in lieu
8of those members under s. 15.197 (20) (b), shall be appointed for terms expiring on
9July 1, 2026.”.
SB70-AA3,82,10 10205. Page 374, line 11: after that line insert:
SB70-AA3,82,11 11 Section 78. 15.07 (3) (bm) 7. of the statutes is created to read:
SB70-AA3,82,1312 15.07 (3) (bm) 7. The prescription drug affordability review board shall meet
13at least 4 times each year.
SB70-AA3,79 14Section 79. 15.735 of the statutes is created to read:
SB70-AA3,82,17 1515.735 Same; attached board. (1) There is created a prescription drug
16affordability review board attached to the office of the commissioner of insurance
17under s. 15.03. The board shall consist of the following members:
SB70-AA3,82,1818 (a) The commissioner of insurance or his or her designee.
SB70-AA3,82,2219 (b) Two members appointed for 4-year terms who represent the
20pharmaceutical drug industry, including pharmaceutical drug manufacturers and
21wholesalers. At least one of the members appointed under this paragraph shall be
22a licensed pharmacist.
SB70-AA3,82,2423 (c) Two members appointed for 4-year terms who represent the health
24insurance industry, including insurers and pharmacy benefit managers.
SB70-AA3,83,3
1(d) Two members appointed for 4-year terms who represent the health care
2industry, including hospitals, physicians, pharmacies, and pharmacists. At least one
3of the members appointed under this paragraph shall be a licensed practitioner.
SB70-AA3,83,54 (e) Two members appointed for 4-year terms who represent the interests of the
5public.
SB70-AA3,83,8 6(2) A member appointed under sub. (1), except for a member appointed under
7sub. (1) (b), may not be an employee of, a board member of, or a consultant to a drug
8manufacturer or trade association for drug manufacturers.
SB70-AA3,83,13 9(3) Any conflict of interest, including any financial or personal association, that
10has the potential to bias or has the appearance of biasing an individual's decision in
11matters related to the board or the conduct of the board's activities shall be
12considered and disclosed when appointing that individual to the board under sub.
13(1).
SB70-AA3,80 14Section 80. Subchapter VI (title) of chapter 601 [precedes 601.78] of the
15statutes is created to read:
SB70-AA3,83,1616 CHAPTER 601
SB70-AA3,83,1817 SUBCHAPTER VI
18 Prescription drug
SB70-AA3,83,1919 affordability review board
SB70-AA3,81 20Section 81. 601.78 of the statutes is created to read:
SB70-AA3,83,21 21601.78 Definitions. In this subchapter:
SB70-AA3,83,23 22(1) “Biologic” means a drug that is produced or distributed in accordance with
23a biologics license application approved under 21 CFR 601.20.
SB70-AA3,83,25 24(2) “Biosimilar” means a drug that is produced or distributed in accordance
25with a biologics license application approved under 42 USC 262 (k) (3).
SB70-AA3,84,2
1(3) “Board” means the prescription drug affordability review board established
2under s. 15.735 (1).
SB70-AA3,84,5 3(4) “Brand name drug” means a drug that is produced or distributed in
4accordance with an original new drug application approved under 21 USC 355 (c),
5other than an authorized generic drug, as defined in 42 CFR 447.502.
SB70-AA3,84,8 6(5) “Financial benefit” includes an honorarium, fee, stock, the value of the stock
7holdings of a member of the board or any immediate family member, and any direct
8financial benefit deriving from the finding of a review conducted under s. 601.79.
SB70-AA3,84,9 9(6) “Generic drug” means any of the following:
SB70-AA3,84,1110 (a) A retail drug that is marketed or distributed in accordance with an
11abbreviated new drug application approved under 21 USC 355 (j).
SB70-AA3,84,1212(b) An authorized generic drug, as defined in 42 CFR 447.502.
SB70-AA3,84,1413 (c) A drug that entered the market prior to 1962 and was not originally
14marketed under a new drug application.
SB70-AA3,84,17 15(7) “Immediate family member” means a spouse, grandparent, parent, sibling,
16child, stepchild, or grandchild or the spouse of a grandparent, parent, sibling, child,
17stepchild, or grandchild.
SB70-AA3,84,18 18(8) “Manufacturer” means an entity that does all of the following:
SB70-AA3,84,2119 (a) Engages in the manufacture of a prescription drug product or enters into
20a lease with another manufacturer to market and distribute a prescription drug
21product under the entity's own name.
SB70-AA3,84,2322 (b) Sets or changes the wholesale acquisition cost of the prescription drug
23product described in par. (a).
SB70-AA3,84,24 24(9) “Pharmacy benefit manager” has the meaning given in s. 632.865 (1) (c).
SB70-AA3,85,2
1(10) “Prescription drug product” means a brand name drug, a generic drug, a
2biologic, or a biosimilar.
SB70-AA3,82 3Section 82. 601.785 of the statutes is created to read:
SB70-AA3,85,8 4601.785 Prescription drug affordability review board. (1) Mission. The
5purpose of the board is to protect state residents, the state, local governments, health
6plans, health care providers, pharmacies licensed in this state, and other
7stakeholders of the health care system in this state from the high costs of prescription
8drug products.
SB70-AA3,85,9 9(2) Powers and duties. (a) The board shall do all of the following:
SB70-AA3,85,1210 1. Meet in open session at least 4 times per year to review prescription drug
11product pricing information, except that the chair may cancel or postpone a meeting
12if there is no business to transact.
SB70-AA3,85,1413 2. To the extent practicable, access and assess pricing information for
14prescription drug products by doing all of the following:
SB70-AA3,85,1715 a. Accessing and assessing information from other states by entering into
16memoranda of understanding with other states to which manufacturers report
17pricing information.
SB70-AA3,85,1818 b. Assessing spending for specific prescription drug products in this state.
SB70-AA3,85,1919 c. Accessing other available pricing information.
SB70-AA3,85,2020 (b) The board may do any of the following:
SB70-AA3,85,2121 1. Promulgate rules for the administration of this subchapter.
SB70-AA3,86,222 2. Enter into a contract with an independent 3rd party for any service
23necessary to carry out the powers and duties of the board. Unless written permission
24is granted by the board, any person with whom the board contracts may not release,

1publish, or otherwise use any information to which the person has access under the
2contract.
SB70-AA3,86,53 (c) The board shall establish and maintain a website to provide public notices
4and make meeting materials available under sub. (3) (a) and to disclose conflicts of
5interest under sub. (4) (d).
SB70-AA3,86,9 6(3) Meeting requirements. (a) Pursuant to s. 19.84, the board shall provide
7public notice of each board meeting at least 2 weeks prior to the meeting and shall
8make the materials for each meeting publicly available at least one week prior to the
9meeting.
SB70-AA3,86,1210 (b) Notwithstanding s. 19.84 (2), the board shall provide an opportunity for
11public comment at each open meeting and shall provide the public with the
12opportunity to provide written comments on pending decisions of the board.
SB70-AA3,86,1513 (c) Notwithstanding subch. V of ch. 19, any portion of a meeting of the board
14concerning proprietary data and information shall be conducted in closed session
15and shall in all respects remain confidential.
SB70-AA3,86,1716 (d) The board may allow expert testimony at any meeting, including when the
17board meets in closed session.
SB70-AA3,86,21 18(4) Conflicts of interest. (a) A member of the board shall recuse himself or
19herself from a decision by the board relating to a prescription drug product if the
20member or an immediate family member has received or could receive any of the
21following:
SB70-AA3,86,2322 1. A direct financial benefit deriving from a determination, or a finding of a
23study or review, by the board relating to the prescription drug product.
SB70-AA3,87,3
12. A financial benefit in excess of $5,000 in a calendar year from any person who
2owns, manufactures, or provides a prescription drug product to be studied or
3reviewed by the board.
SB70-AA3,87,74 (b) A conflict of interest under this subsection shall be disclosed by the board
5when hiring board staff, by the appointing authority when appointing members to
6the board, and by the board when a member of the board is recused from any decision
7relating to a review of a prescription drug product.
SB70-AA3,87,118 (c) A conflict of interest under this subsection shall be disclosed no later than
95 days after the conflict is identified, except that, if the conflict is identified within
105 days of an open meeting of the board, the conflict shall be disclosed prior to the
11meeting.
SB70-AA3,87,1512 (d) The board shall disclose a conflict of interest under this subsection on the
13board's website unless the chair of the board recuses the member from a final
14decision relating to a review of the prescription drug product. The disclosure shall
15include the type, nature, and magnitude of the interests of the member involved.
SB70-AA3,87,1816 (e) A member of the board or a 3rd-party contractor may not accept any gift or
17donation of services or property that indicates a potential conflict of interest or has
18the appearance of biasing the work of the board.
SB70-AA3,83 19Section 83. 601.79 of the statutes is created to read:
SB70-AA3,87,21 20601.79 Drug cost affordability review. (1) Identification of drugs. The
21board shall identify prescription drug products that are any of the following:
SB70-AA3,87,2522 (a) A brand name drug or biologic that, as adjusted annually to reflect
23adjustments to the U.S. consumer price index for all urban consumers, U.S. city
24average, as determined by the U.S. department of labor, has a launch wholesale
25acquisition cost of at least $30,000 per year or course of treatment.
SB70-AA3,88,4
1(b) A brand name drug or biologic that, as adjusted annually to reflect
2adjustments to the U.S. consumer price index for all urban consumers, U.S. city
3average, as determined by the U.S. department of labor, has a wholesale acquisition
4cost that has increased at least $3,000 during a 12-month period.
SB70-AA3,88,75 (c) A biosimilar that has a launch wholesale acquisition cost that is not at least
615 percent lower than the referenced brand biologic at the time the biosimilar is
7launched.
SB70-AA3,88,118 (d) A generic drug that has a wholesale acquisition cost, as adjusted annually
9to reflect adjustments to the U.S. consumer price index for all urban consumers, U.S.
10city average, as determined by the U.S. department of labor, that meets all of the
11following conditions:
SB70-AA3,88,1712 1. Is at least $100 for a supply lasting a patient for a period of 30 consecutive
13days based on the recommended dosage approved for labeling by the federal food and
14drug administration, a supply lasting a patient for a period of fewer than 30 days
15based on the recommended dosage approved for labeling by the federal food and drug
16administration, or one unit of the drug if the labeling approved by the federal food
17and drug administration does not recommend a finite dosage.
SB70-AA3,88,2018 2. Increased by at least 200 percent during the preceding 12-month period, as
19determined by the difference between the resulting wholesale acquisition cost and
20the average of the wholesale acquisition cost reported over the preceding 12 months.
Loading...
Loading...